I am a pediatric oncologist with extensive experience in the treatment of sarcomas in children and young adults. At Memorial Sloan Kettering, we treat more children and young adults with sarcoma than anywhere else in the country. I am proud to be part of a team that takes a comprehensive approach to develop a personalized regimen of care, with the goal of saving the lives of our young patients.
Many of our patients are adolescents and young adults, who are transitioning from childhood dependence on their parents to independent living. We help them maintain their independence in every way during their cancer care, while still ensuring that they have the emotional and practical support of their family members.
Many of the types of cancer that arise in young adults are quite rare, and very few oncologists have experience treating them. Some young adults have a form of cancer that is seen much more commonly in children and adolescents. The team with the greatest expertise in managing their specific disease may therefore be based in the Department of Pediatrics. At Memorial Sloan Kettering, we believe that the most important service we provide to patients is a multidisciplinary healthcare team.
In addition to patient care, I direct clinical research aimed at developing and evaluating new therapies for sarcomas. I served for five years as Head of the Bone Sarcoma Strategy Group for the Children’s Cancer Group, where I directed national clinical trials for osteosarcoma and Ewing sarcoma. I have also conducted clinical trials at Memorial Sloan Kettering for the treatment of newly diagnosed and recurrent osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma, undifferentiated sarcoma, and other unusual tumors that occur in children and young adults.
One area of study that I feel passionate about is the evaluation of muramyl tripeptide phosphatidyl ethanolamine (MTP-PE), a promising drug for osteosarcoma which has been approved for use in Europe. It increases the ability of white blood cells to attack osteosarcoma tumor cells and to help the body to destroy the tumor.
Education is another important part of my role at Memorial Sloan Kettering. I serve as Vice Chair of Academic Affairs in the Department of Pediatrics. Memorial Sloan Kettering is proud to offer one of the most comprehensive training programs in pediatric hematology/oncology in the country. With a very large number of patients and a faculty with decades of experience, our trainees see an unparalleled variety of clinical challenges. Fellows also have the benefit of working with nearby institutions such as Weill Cornell Medical College and The Rockefeller University.
As a result of my patient care experience and research, I have authored or co-authored over 135 publications about sarcomas. In recognition of my work, I received the Willet E. Whitmore Award for Clinical Excellence from Memorial Sloan Kettering in 1995. I served as president of the Connective Tissue Oncology Society, a leading academic society devoted to the study of sarcomas. I am a member of the National Cancer Institute Physician Data Query Pediatric Board.
I am also the founding medical director for Happiness is Camping, a summer camp for children with cancer. I have had the extraordinary opportunity to help give these kids a respite from the rigors of cancer therapy and to see them blossom and thrive away from the hospital environment.
- Clinical Expertise: Pediatric Oncology; Osteosarcoma; Ewing Sarcoma; Leukemias; Rhabdomyosarcoma and Other Soft Tissue Developmental Tumors of Childhood
- Languages Spoken: English; French; Spanish
- Education: MD, Mount Sinai School of Medicine
- Residencies: Mount Sinai Medical Center (New York)
- Fellowships: Memorial Sloan Kettering Cancer Center; The New York Hospital/Cornell Medical Center
- Board Certifications: Pediatrics; Pediatric Hematology-Oncology
Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan Kettering experience and a literature review.. J Clin Oncol. 2001; 19 :870-880
Shamberger RC, Laquaglia MP, Krailo MD, Miser JS, Pritchard DJ, Gebhardt MC, Healey JH, Tarbell NJ, Fryer CJ, Meyers PA, Grier HE.. Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection.. J Thorac Cardiovasc Surg. 2000; 119 :1154-61
Kushner BH, Heller G, Cheung NK, Wollner N, Kramer K, Bajorin D, Polyak T, Meyers PA.. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.. J Clin Oncol 1998; 16 :3016-20
Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH.. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma.. J Bone Joint Surg Am. 1998; 80 :1020-33
Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH.. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan Kettering (T12) protocol.. J Clin Oncol 1998; 16 :2452-8
de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR, Pardo-Mindan FJ, Ginsberg J, Womer R, Lawlor ER, Wunder J, Andrulis I, Sorensen PH, Barr FG, Ladanyi M.. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing sarcoma. J Clin Oncol 1998; 16 :1248-55
Imbriaco M, Yeh SD, Yeung H, Zhang JJ, Healey JH, Meyers P, Huvos AG, Larson SM.. Imbriaco M, Yeh SD, Yeung H, Zhang JJ, Healey JH, Meyers P, Huvos AGThallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma, Larson SM.. Cancer 1997; 80 :1507-12
O’Reilly R, Link M, Fletcher B, Gebhardt M, Krance R, Meyers P, Neff J, Schwartz C.. NCCN pediatric osteosarcoma practice guidelines. The National Comprehensive Cancer Network.. Oncology 1996; 10 :1799-806
Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, Merchant TE, Boulad F, Cheung NK, Bonilla MA, Crouch G, Kelleher JF Jr, Steinherz PG, Gerald WL.. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy.. J Clin Oncol 1996; 14 :1526-31
Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, Wollner N, Casper ES, Aledo A, Heller G, et al.. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing sarcoma, in children and young adults. J Clin Oncol 1995; 13 :2796-804
Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, et al.. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma.. N Engl J Med 1992; 326 :1301-8
Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G.. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan Kettering experience. J Clin Oncol 1992; 10 :5-15
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Paul A. Meyers
Clinical Trials Co-Investigated by Paul A. Meyers
- A Phase II Study of Irinotecan and Temozolomide in Combination with Existing High-Dose Chemotherapy for Patients Newly Diagnosed with Ewing Sarcoma
- A Pilot Trial of Irinotecan, Temozolomide, and Bevacizumab plus High-Dose Chemotherapy for Newly Diagnosed Patients with Desmoplastic Small Round Cell Tumor
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more